Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04538885
Other study ID # CHIN-PLAGH-MP-04
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date September 10, 2020
Est. completion date May 30, 2021

Study information

Verified date September 2020
Source Chinese PLA General Hospital
Contact Meirong Li, doctor
Phone 010-66936345
Email meirong811225@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Poor incision healing is a common complication after abdominal surgery, mainly manifested as incision dehiscence, subcutaneous fat liquefaction, malnutrition, and incision infection. Poor healing of the incision will increase the patient's pain and prolong the patient's hospital stay, and the choice of wound treatment is closely related to the wound healing effect. Mesenchymal stem cells mainly rely on paracrine effects to exert their therapeutic effects and obtain better therapeutic effects in wound healing. Here, the pleiotropic factors secreted from mesenchymal stem cells (MSCs-PFs) will be used to treat patients with poor healing after surgery to evaluate its effectiveness and safety.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date May 30, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Wound size <10X10cm2, the wound base only involves subcutaneous and muscle tissue;

2. Underwent surgical treatment, all incisions were type I, and the incisions healed poorly and delayed healing after 1 week;

3. There is inflammatory reaction at the incision, but no clear indication of infection, or severe infection of the incision.After debridement and dressing change, the infection is controlled and the fresh granulation period is entered

4. Men or women older than 17 years old and younger than 75 years old;

5. Psychologically stable, able to complete the test process.

Exclusion Criteria:

1. Wound size>10X10cm2, the wound base is as deep as the chest and abdominal cavity, causing infection or osteomyelitis in the chest and abdominal cavity;

2. Surgical incision with purulent infection, local purulent secretions can be seen;

3. Those with obvious body temperature and white blood cell elevation, local purulent secretions have positive bacterial culture;

4. Patients with diabetes;

5. Glucocorticoid users;

6. Patients with immune dermatosis;

7. Neoplastic wounds, such as wounds after skin cancer resection, or skin wounds caused by tumor invasion;

8. Psycho-psychological disorders and poor compliance.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
The pleiotropic factor derived from mesenchymal stem cells
The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Chinese PLA General Hospital Gansu Provincial Maternity and Child-Care Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Wound healing time and healing rate Judgment criteria for incision recovery (4 weeks after treatment): Cure: the patient's incision is completely or basically healed, and the surrounding skin returns to normal; markedly effective: the patient's incision is recovered> 1/2, and the surrounding skin returns to normal; effective: the patient's incision is recovered <1 /2, and the surrounding skin returned to normal; invalid: the patient's incision had no obvious changes, and the surrounding skin color had no obvious improvement. 1 month